Comparison of Iodine + Isopropyl Alcohol Versus Iodine + Antimicrobial Sealant for Skin Preparation
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose if this study is to determine whether a microbial sealant (iodine + cyanoacrylate) [InteguSEAL®, Kimberly-Clark] reduces surgical site infections when compared to iodine and isopropyl alcohol (povacrylex in isopropyl alcohol) [Duraprep®] in oncologic surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Surgical Site Infection |
Device: 2-octyl cyanoacrylate [InteguSEAL®] Device: Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M] |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Comparative Study of a Iodine + Cyanoacrylate (Integuseal) vs. Iodine and Isopropyl Alcohol in Skin Preparation for Prevention of Surgical Site Infections in Oncologic Surgery |
- Surgical site infection [ Time Frame: 30-45 days ] [ Designated as safety issue: No ]Patients we'll be followed prospectively by direct observation to evaluate if a surgical infection occurs. After 30 days of follow-up, patients will be classified as having or not a surgical site infection using the CDC criteria.
- Cost analysis [ Time Frame: 30-45 days ] [ Designated as safety issue: No ]We'll be doing a cost-efectiveness analysis at the end of the study considering the treatment arm, complications developed from surgery to end of follow-up and costs for its treatment.
| Estimated Enrollment: | 1200 |
| Study Start Date: | May 2009 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 2-octyl cyanoacrylate
As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
|
Device: 2-octyl cyanoacrylate [InteguSEAL®]
At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
Other Name: InteguSEAL® (Kimberly Clark)
|
|
Active Comparator: iodine povacrylex in isopropyl alcohol
Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
|
Device: Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]
At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
Other Name: Duraprep® (3M)
|
Detailed Description:
Patient's skin flora is a major source of pathogens, and microbial contamination of the surgical site is a likely precursor of SSI. A variety of skin products may be used, including iodophors, alcohol-containing products, and clorhexidine gluconate. Despite these perioperative tactics, bacteria continue to survive at the skin level and migrate to contaminate the wound.
A microbial sealant (InteguSEAL®, Kimberly-Clark) that uses cyanoacrylate to seal endogenous skin flora has demonstrated to reduce wound contamination. The efficacy of the microbial sealant in preventing SSI has been tested in cardiovascular surgery and open inguinal hernia repair, with a reduction on SSI rate when compared to standard skin preparations. This cyanoacrylate has not been tested in oncologic surgeries.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients >= 18 years undergoing elective clean or clean-contaminated breast, gynecologic or digestive tract surgery
- Accepts to participate and signs the informed consent form
- Have a telephone number to be contacted after surgery
Exclusion Criteria:
- Previous allergy to one of the study products
- Two or more procedures in different anatomical sites at the same time / surgery (v.g. hysterectomy and mastectomy)
- Pregnancy
- Breast feeding
- Contaminated or infected surgeries
Contacts and Locations| Contact: Diana Vilar-Compte, MD, MsC | +52 555 628 0400 ext 262 | parakalomx@yahoo.com.mx |
| Mexico | |
| National Institute of Cancerology | Recruiting |
| Mexico City, DF, Mexico, 14080 | |
| Contact: Diana Vilar-Compte, MD, MsC +52 555 628 0400 ext 262 parakalomx@yahoo.com.mx | |
| Principal Investigator: | Diana Vilar-Compte, MD;MsC | Instituto Nacional de Cancerologia, Columbia |
More Information
No publications provided
| Responsible Party: | Diana Vilar-Compte, MD, MsC, Departmentof Infectious Diseases. Instituto Nacional de Cancerología |
| ClinicalTrials.gov Identifier: | NCT01110772 History of Changes |
| Other Study ID Numbers: | 09003INI |
| Study First Received: | April 23, 2010 |
| Last Updated: | April 26, 2010 |
| Health Authority: | Mexico: Ethics Committee |
Keywords provided by National Institute of Cancerología:
|
Surgical site infection Skin preparation Cost analysis |
Additional relevant MeSH terms:
|
Ethanol Iodine Cadexomer iodine Anti-Infective Agents, Local Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
Central Nervous System Depressants Physiological Effects of Drugs Central Nervous System Agents Trace Elements Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 21, 2013